Transcatheter heart valve developer Direct Flow Medical has raked in $32 million, including $17 million in equity and the second tranch of $15 million from a $50 million debt facility by PDL BioPharma. The money will go toward completing a U.S. pivotal trial for its Transcatheter Aortic Valve System, as well as further commercialization in Europe where the system is already marketed. Direct Flow also hired its first Chief Commercial Officer to support global growth, Chris Richardson, who has a 25-year career in cardiac device development and commercialization. New investor SV Life Sciences led the equity financing along with a new, undisclosed strategic investor. Release